MLND News and Press, Millendo Therapeutics From 12/04/19

Millendo Therapeutics (NASDAQ: MLND ) is down 18.8% in light postmarket trade after its proposed equity offering is said to amount to $25M in shares. More news on: Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. Millendo also intends to grant the under...

Millendo Therapeutics ( MLND ) is a solid biotech, which has already received positive results from a proof of concept study using livoletide to treat patients with Prader-Willi Syndrome ((PWS)). Based on positive preliminary data, it was able to initiate a phase 2b/3 study. There is a big c...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Millendo Therapeutics (NASDAQ: MLND ): Q3 GAAP EPS of -$0.87 misses by $0.04 . More news on: Millendo Therapeutics, Inc., Earnings news and commentary, , Read more ...

– Livoletide pivotal study in Prader-Willi syndrome (PWS) completed recruitment for patients ages 8 to 65 and is on track to report topline results in 1H20 – – Company to host PWS Breakfast Symposium on Thursday, November 14, 2019, to discuss potential new treatmen...

– ZEPHYR study successfully recruits over 150 patients in eight months for Phase 2b portion of pivotal Phase 2b/3 study of livoletide in PWS patients ages 8 to 65 – – Recruitment will continue for a separate cohort of PWS patients ages 4 to 7 – Millen...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conferenc...

– Prominent PWS clinical expert along with company management will discuss disease epidemiology, current treatment landscape and livoletide as a potential new therapy for PWS patients – – Live webcast to begin at 8:30 a.m. EST – Millendo Therapeutics, ...